To read the full story, subscribe or sign in.

South Korea's RNA-focused biopharma Rznomics secures ₩12 billion in series A

Oct. 30, 2019

HONG KONG – South Korean startup Rznomics Inc. has recently secured ₩12 billion (US$10 million) in a series A investment. The Gwangju-based company focuses on cancer treatment development based on RNA platform technology.

BioWorld BioWorld Asia Newco news

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 10, 2025

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...